Novo Nordisk A/S
corporate_fare Company Profile
Novo Nordisk A/S (NYSE:NVO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for NVO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-29, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for NVO spans 6-K, 20-F.
Recent high-impact activity:
- Ozempic 2 mg Shows 6% Lower Cardiovascular Risk vs Mounjaro in Real-World Study
- Novo Nordisk Inks $2.6B Deal for Hengrui's Oral Obesity Drug
- Novo Nordisk Inks $1.3B Deal for Nanexa's Drug-Delivery Tech
- Novo Nordisk's FREHEMGO Secures CHMP Backing for EU Approval in Haemophilia A
- Novo Nordisk Inks $1.4B AI Drug Discovery Deal with Orbis Medicine
Financial Snapshot
Short Interest & Short Volume
2.92 days to coverFINRA reported short interest of 26,339,706 shares in NVO as of the September 15, 2026 settlement, a 16.8% decrease from the prior period — about 2.9 days to cover at its recent average daily volume. On October 2, 2026, 47.3% of NVO volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
NVO files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.